![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
MIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology firm targeted on the invention, analysis and improvement of new and efficient remedies for central nervous system (CNS) issues, at present introduced that Camac Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney, and Avi Geller (collectively, the “Camac Group”) glad the mandatory necessities to name a Special Meeting of Stockholders (“Special Meeting”).
The Company was notified that the Camac Group demonstrated the requisite votes on September 28, 2022, and notes that, opposite to their public statements, the Camac Group’s notifications prior to that date have been invalid.
Pasithea will name a Special Meeting in accordance with the Company’s bylaws. Additional particulars in regards to the Special Meeting shall be forthcoming. There is not any motion required by stockholders.
The Company acknowledged, “During our first year as a public company, Pasithea has made significant progress towards our mandate to develop novel and groundbreaking drugs, including achieving positive preclinical results for our drug discovery programs, strengthening our team of scientists, expanding our portfolio with complementary CNS therapies with significant potential, and enhancing our recently reelected Board of Directors. We are excited about Pasithea’s future scientific and value creation prospects, and look forward to continued engagement with our stockholders.”
McDermott Will & Emery LLP are serving as authorized advisor to the Company and Kingsdale Advisors is serving as an advisor in reference to the actions of the Camac Group.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a biotechnology firm targeted on the invention, analysis and improvement of new and efficient remedies for central nervous system (CNS) issues. With an skilled crew of consultants within the fields of neuroscience and psychopharmacology, Pasithea is creating new molecular entities for the therapy of psychiatric and neurological issues, together with Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the wants of sufferers at present struggling with psychological sickness by offering entry to IV ketamine infusions each in clinics and in-home settings.
Forward Looking Statements
This press launch incorporates statements that represent “forward-looking statements.” Forward-looking statements are topic to quite a few situations, many of that are past the management of the Company. While the Company believes these forward-looking statements are affordable, undue reliance shouldn’t be positioned on any such forward-looking statements, that are based mostly on info accessible to the Company on the date of this launch. These forward-looking statements are based mostly upon present estimates and assumptions and are topic to numerous dangers and uncertainties, together with, with out limitation, these set forth within the Company’s filings with the SEC. Thus, precise outcomes could possibly be materially totally different. The Company undertakes no obligation to replace these statements whether or not because of this of new info, future occasions or in any other case, after the date of this launch, besides as required by legislation. Such forward-looking statements are topic to dangers (together with these set forth within the Company’s Form 10-Ok for the fiscal 12 months ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which might trigger precise outcomes to differ from the forward-looking statements.
Important Additional Information and Where to Find It
This communication could also be deemed solicitation materials in respect of the Special Meeting. The Company plans to file a proxy assertion with the Securities and Exchange Commission, in reference to the solicitation of proxies for the Special Meeting. Stockholders are urged to learn such proxy assertion (together with any amendments or dietary supplements thereto) and some other related paperwork that the Company recordsdata with the SEC rigorously of their entirety after they turn into accessible as a result of they may include essential info.
Certain Information Regarding Participants to the Solicitation
Pasithea, its administrators and sure of its govt officers and workers are deemed to be individuals in a solicitation of requests not to vote for the Camac Group’s proposal on the Special Meeting (the “Special Meeting Solicitation”). Information relating to the identification of these potential individuals and their direct or oblique pursuits, by safety holdings or in any other case, is about forth within the Consent Revocation Solicitation Statement filed by Pasithea with the Securities and Exchange Commission on July 28, 2022.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: [email protected]
Michael Fein
Kingsdale Advisors
T: 646-651-1641
E: [email protected]
Pasithea Therapeutics Corp. Media Contact
Paul Caminiti/Nicholas Leasure
Reevemark
T: 212-433-4600
E: [email protected]
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
